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Prion diseases are neurodegenerative, infectious disorders characterized by the aggregation of a
misfolded isoform of the cellular prion protein (PrPC). The infectious agent – termed prion – is
mainly composed of misfolded PrPSc. In addition to the central nervous system prions can colonize
secondary lymphoid organs and inﬂammatory foci. Follicular dendritic cells are important extra-
neural sites of prion replication. However, recent data point to a broader range of cell types that
can replicate prions. Here, we review the state of the art in regards to peripheral prion replication,
neuroinvasion and the determinants of prion replication competence.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Prion diseases: infectious neurodegenerative disorders in
humans and animals
Prion diseases, also designated as transmissible spongiform
encephalopathies (TSEs), are infectious and invariably fatal neuro-
degenerative disorders affecting humans and animals [1–3]. These
include kuru, Creutzfeldt–Jakob disease (CJD), Gerstmann–Sträuss-
ler–Scheinker disease (GSS) and fatal familial insomnia (FFI) in
humans, as well as scrapie of sheep and goats, bovine spongiform
encephalopathy (BSE) or ‘‘mad cow disease” of cattle and chronic
wasting disease (CWD) of deer and elk [1–3].
The last century has witnessed a tremendous series of tragic
episodes related to prion diseases [2]. Until the middle of the
20th century kuru decimated Papua New Guinea aborigines
devoted to ritualistic consumption of central nervous system
(CNS)-derived tissues [4]. The employment of prion-contaminated
gonadotropins, corneal transplantations, dura mater grafts and sur-
gical instruments has resulted in more than 250 cases of iatrogenic
CJD in the 1970s with drastic implications for clinical practice [2].
Starting from 1986, the epidemic of BSE has affected more than
280 000 cattle, provoking a food crisis with unprecedented, world-
wide economic consequences. Transmission of the BSE agent to hu-
mans has been regarded as the cause of a new clinico-pathological
entity, termed variant CJD (vCJD), which was ﬁrst described in
1996 [5,6] and has so far caused death in 212 individuals (http://chemical Societies. Published by E
. Heikenwalder).www.cjd.ed.ac.uk/vcjdworld.htm). The rising incidence of vCJD in
the late 1990s and the possibility that millions of people have been
exposed to BSE-contaminated meat have evoked fears of an
upcoming pandemic.
2. The versatile prion
The beginning of the present century has brought the encourag-
ing news of a stabilizing or subsiding incidence of vCJD, but novel
alarming facts are indicating that prions are much more versatile
than previously thought. The occurrence of horizontal transmis-
sion of vCJD by blood transfusions [7,8] has indicated that vCJD pri-
ons can recycle among subclinical humans. This trouble was not
necessarily predicted by mouse models [9,10] and poses a new,
worldwide challenge for health authorities in terms of donor defer-
ral criteria and blood quality surveillance, while a speciﬁc and sen-
sitive test for the detection of prions in human blood is still
pending [11]. Only recently, the Health Protection Agency of the
United Kingdom has reported a case of a hemophilic patient
who, most likely, has acquired vCJD prions through Factor VIII
preparation derived from plasma donated by a ‘‘preclinical” vCJD
patient (http://www.hpa.org.uk). Moreover, recent reports from
work with kuru patients in New Guinea indicate that heterozygos-
ity at polymorphic codon 129 (129 M/V) of PRNP, the gene encod-
ing the human prion protein, could lead to incubation periods
exceeding 50 years [12].
These ﬁndings demonstrate that we need to learn more about
horizontal prion transmission in humans, how to detect subclinicallsevier B.V. All rights reserved.
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health. Future observations will have to show whether any of the
above mentioned will impact on the epidemiology of vCJD.
Moreover, a recrudescence of scrapie outbreaks among Euro-
pean sheep ﬂocks has been described in the last years and new
cases of BSE and vCJD have been reported in countries and conti-
nents previously deemed prion-free [13]. In this regard it is impor-
tant to mention that is unknown by today whether scrapie prions
can pose a potential health risk to humans.
In addition, an atypical BSE strain – called bovine amyloidotic
spongiform encephalopathy (BASE) – has been identiﬁed in differ-
ent countries displaying biochemical properties similar to a sub-
group of sporadic CJD (sCJD) [14]. These data questioned whether
a temporarily deﬁned increase in sCJD cases (e.g. in Switzerland)
was a result of BASE transmission to humans [15]. Furthermore,
the spread of CWD of cervids in North America and the potential
dietary-exposure of millions of individuals to prion-contaminated
venison have raised the still unsolved question of human suscepti-
bility to CWD prions [16].
Recent inventions and reﬁnements in the technologies for
detection of the disease-associated prion protein have signiﬁcantly
extended and shifted our knowledge about prion tropism [17]. The
general belief that sCJD prions are rather conﬁned to the CNS when
compared to vCJD prions, which also colonize peripheral organs,
was ﬁrst shaken by investigating extraneural organs of sCJD pa-
tients using novel or advanced techniques [18–20]. Disease-associ-
ated prion proteins have been detected in the olfactory epithelium
[21], as well as in spleen and muscle tissue of sCJD victims [19].
Moreover, prion infectivity was demonstrated in saliva, milk, blood
and muscles of TSE affected individuals [22–25] and, as substanti-
ated below, in chronically inﬂamed organs (e.g. mammary gland,
liver and kidney) [26–28]. Scrapie infection in nephritic mice leads
to urinary prion secretion (also termed prionuria), even at subclin-
ical stage [29]. Further, moderate intestinal inﬂammation at the
time of prion exposure increases the susceptibility to orally admin-
istered prions [30]. Taken together, these observations indicate
that environmental factors (e.g. inﬂammation) can change the
prion tropism to organs hitherto believed prion-free [17,28,31].
Nevertheless, peripheral prion accumulation was reported to occur
also in excretory organs and body ﬂuids under non-inﬂammatory
conditions, however to much less degree [25,32]. In summary,
these data question the current risk assessment of high-infectivity
organs in humans and animals, so far mainly including the CNS and
the lymphoreticular system (LRS).
Although prion diseases have always been regarded as a
‘‘sui generis” class of infectious maladies, recent ﬁndings have
challenged this notion. Data from murine models of Alzheimer’s
disease indicate that exogenous Ab amyloid is capable of inducing
cerebral Ab amyloidosis with disease phenotypes that are gov-
erned by both the host and the inoculum, features reminiscent of
prion strains [33]. These ﬁndings are fascinating and support the
hypothesis that pathogenic mechanisms operating in prion dis-
eases might be shared by other neurodegenerative disorders
[34,35].
Despite substantial progress in our understanding of prion
pathogenesis, a number of crucial questions still remain unan-
swered. These include the exact nature of the infectious agent,
the cellular and molecular mechanisms of central and peripheral
prion replication, the deﬁning traits of prion strains, the determi-
nants of prion toxicity, the routes of horizontal transmission and
the mechanistic basis of species barrier.
Here, we review the current state of art in prion biology and
prion immunology. In addition we examine the currently
available tools to detect prions and summarize the immunologi-
cal interventional strategies against prion diseases explored so
far.3. The infectious agent
The etiologic agent of TSEs is termed prion (proteinaceous infec-
tious only) and displays unconventional properties, such as resis-
tance to UV irradiation, exposure to high pressures or
temperatures and formaldehyde treatment. According to the pro-
tein-only hypothesis, it is devoid of informational nucleic acid
and coincides with scrapie prion protein (PrPSc), an abnormal iso-
form of PrPC, which is capable of converting PrPC into a likeliness
of itself [36].
Despite considerable efforts, no posttranslational chemical
modiﬁcations that might discriminate between PrPC and PrPSc
were found, indicating that solely conformational changes distin-
guish the two PrP isoforms [37]. The ﬁne structure of PrPC is known
at the atomic level [38]. On the other hand, no high-resolution
structure is available for PrPSc, but limited data from low-resolu-
tion structural methods are compatible with a signiﬁcantly differ-
ent conformation of PrPSc with respect to PrPC [39,40].
4. Prion strains
The prion strains phenomenon adds a further level of complex-
ity to the question of protein structure [41]. Prion strains are TSE
isolates or sources of prion infectivity that, upon inoculation into
genetically identical hosts, cause disease with consistent charac-
teristics, including incubation time, lesion proﬁles within the CNS
and even tropism for extracerebral cell types [41–43]. To accom-
modate the existence of different prion strains within the frame
of the protein-only hypothesis, one should postulate that PrPSc
must exist in various distinct pathological conformations, each
one able to impart its own conformation onto PrPC, thus culminat-
ing in distinct disease characteristics [41,44].5. Detection of prions: from mice to test-tubes
In this context, detection of bona ﬁde prions is achievable only
through determination of prion infectivity. This is classically per-
formed by bioassay in which serial dilutions of the test material
are inoculated into experimental animals, and the dilution at which
50% of the animals contract the disease (termed ID50) is determined
[45]. However, this system suffers from inaccuracy, is time-consum-
ing and is limited by the requirement of scores of animals.
These limitations are partly overcome by a recently developed
assay based on prion-susceptible cell lines, termed scrapie cell
endpoint assay [46]. This method combines the sensitivity and
intrinsic biological validity of the bioassay (i.e. direct measurement
of infectivity) with the speed, convenience and amenability to
high-throughput automation of an in vitro system. Extension of
the susceptibility of neuronal cell lines used in this assay, currently
restricted to various murine prion strains, could pave the way for a
sensitive test to detect prion infectivity, with both medical and vet-
erinarian applications.
As an alternative to prion infectivity assessment, various bio-
chemical or biophysical peculiarities of PrPSc, presumably stem-
ming from its differential conformation with respect to PrPC, can
be operationally used as surrogate markers for prion infection.
The ﬁrst reliable surrogate marker of prion infectivity is its par-
tial resistance against proteolytic degradation. Incubation with
50 lg/mL of proteinase K (PK) at 37 C for 2 h does not degrade
the carboxyl-proximal domain of the disease-associated prion pro-
tein, nor decrease the infectious titer of the prion preparation [47].
More than 25 years after it was ﬁrst described, the detection of PK-
resistant prion protein still remains the gold standard for the bio-
chemical diagnosis of prion diseases and forms the basis of all the
marketed BSE tests.
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formed in combination with histological techniques. In particular,
blotting either parafﬁn-embedded tissue (PET blots) [48] or cryo-
sections (histoblots) [49] onto nitrocellulose membrane, followed
by digestion with PK and decoration with anti-PrP antibodies en-
ables the detection of PK-resistant prion protein in situ, thus pro-
viding precious information about topographic distribution of the
pathologic protein in disease tissues.
PK-resistant prion protein is not always easily detectable in tis-
sues or body ﬂuids from affected hosts. In 2001 a signiﬁcant step
towards a more sensitive method of detection of PrPSc has been
achieved [18]. Selective precipitation of PrPSc from tissue homoge-
nates with sodium phosphotungstic acid results in the concentra-
tion of PrPSc from large volumes of test material. Combination of
this preparative step with immunoblot detection results in in-
creased sensitivity of Western blot analysis by up to three orders
of magnitude and has been extensively exploited to detect PrPSc
in extraneural sites of TSE victims [18,19]. In the same year another
milestone for sensitive detection of the pathological prion protein
is represented by the so-called protein misfolding cyclic ampliﬁca-
tion (PMCA) [50]. Analogously to a PCR reaction, PMCA generates
PrPSc from monomeric substrates and a small amount of template
PrPSc. Ampliﬁcation of PrPSc is achieved through cycles of sonica-
tion, which disrupts the PrPSc aggregates, and elongation, that en-
tails incubation with the monomeric substrate which is recruited
by the misfolded prion protein, and is accompanied by an increase
in prion infectivity. This technology succeeded to detect ampliﬁ-
able PrPSc in blood of prion-infected hamsters in the presymptom-
atic phase of the disease [51], suggesting that PMCAmight prove to
become a sensitive non-invasive method for early diagnosis of
prion diseases. However, the fact that PMCA can generate de novo
prions from non-infectious material [52] emphasizes that the tech-
nique may be prone to false positives, thus questioning its useful-
ness as a diagnostic tool [11]. Besides this limitation, PMCA could
also prove instrumental in expanding our understanding of prion
replication mechanisms [11].
An additional strategy to detect the disease-associated protein
relies on the assumption that, upon conversion to PrPSc, at least
some epitopes of PrPC are buried in the aggregates. The measure-
ment of the differential binding of anti-PrP antibodies to native
vs. denaturated prion protein, which constitutes the
basis of the conformation-dependent immunoassay, provides a
sensitive assay to detect PrPSc and a good tool to investigate
the existence of conformational differences between distinct
strains of prions [53].6. The physiological function of PrPC: PrPC and the CNS
PrPC is tethered to the external surface of cells by a glycosyl
phosphatidyl inositol (GPI) anchor and is enriched in detergent-
resistant microdomains of cellular membrane termed lipid rafts.
It undergoes facultative N-linked glycosylation at two sites, which
results in un-, mono- or diglycosylated moieties.
The expression pattern of PrPC is broad, developmentally regu-
lated and includes the nervous system (with high PrPC levels in
synaptic membranes of neurons and on astrocytes), secondary
lymphoid organs, skeletal muscle, kidney and heart. PrPC is highly
conserved among mammals, and paralogues thereof are present in
birds, reptiles, amphibians and possibly in ﬁsh. No naturally occur-
ring Prnp-null alleles have ever been observed in any mammalian
species. These observations suggest a broad and conserved func-
tion for the protein [2].
Despite intensive investigations and the availability of Prnp0/0
mice since 1992, the physiological function of PrPC has not been
clearly identiﬁed. Prnp ablation per se does not elicit neurodegen-eration [54], even when induced postnatally [55]. Therefore, prion
pathology is unlikely to be the result of a loss of PrPC function.
However, PrPSc conversion might alter the physiological function
of PrPC and confer a toxic dominant function. This could include al-
tered signal transduction, enzymatic activity, and change in sub-
strate speciﬁcity or protein binding properties. In this scenario,
elucidating the physiological function of PrPC may be instrumental
to deciphering the mechanisms of prion pathogenesis and eventu-
ally to devising tailored interventional strategies. A non-exhaustive
list of putative functions of PrPC includes signal transduction, reg-
ulation of circadian rhythm, copper binding, proliferation of neural
precursors, processing of sensory information by the olfactory sys-
tem, cellular iron uptake and transport, pro-apoptotic or anti-
apoptotic function and others [56].
7. PrPC, prion replication and neurodegeneration
The only universally acknowledged function of PrPC is to repli-
cate prions and mediate their toxicity: Prnp0/0 mice are resistant to
prion infection [54]. Brain tissue devoid of PrPC is not damaged by
exogenous PrPSc, as demonstrated by reﬁned brain grafting exper-
iments of PrPC overexpressing brain tissue into Prnp0/0 brains [57].
Surprisingly, depleting endogenous neuronal PrPC in prion-infected
mice reverses early spongiosis and prevents neuronal loss and pro-
gression to clinical disease, despite the accumulation of extraneu-
ronal PrPSc to levels normally found in terminally sick wild-type
(wt) animals [55]. Moreover, scrapie-infected transgenic mice
exclusively expressing a monomeric, soluble secreted form of PrPC
that lacks the GPI anchor do not develop overt prion disease, while
PrPSc accumulate in their brains in form of amyloid plaques [58].
Collectively, these ﬁndings indicate that PrPSc is per se innocuous
and that prion replication avails itself of membrane-bound PrPC
on neurons to elicit neurotoxicity [59].
Recently, Strittmatter and colleagues have provided evidence
that PrPC is a high-afﬁnity cell-surface receptor for soluble syn-
thetic Ab oligomers on neurons and might play a central role in
the pathophysiological process of Alzheimer’s disease [60]. This
ﬁnding is intriguing and future investigations will have to eluci-
date whether PrPC binds to naturally occurring Ab oligomers in
vivo. In addition, the clinical relevance and the therapeutic impli-
cations of this discovery have to be clariﬁed [61].8. PrPC and the immune system
With regard to the immune system, PrPC is expressed in T and B
lymphocytes, natural killer (NK) cells, platelets, erythrocytes,
monocytes, dendritic cells (DCs) and follicular dendritic cells
(FDCs), albeit with signiﬁcant differences across species and among
states of maturation and subsets of immune cells [17]. PrPC has
been implicated in T lymphocyte development, activation and in
the interaction of T lymphocytes and DCs [62,63]. Overexpression
of PrPC in transgenic mice has been shown to alter T cell develop-
ment in the thymus via local generation of an antioxidant milieu
[64], but recent work of Zabel et al. has indicated that this pheno-
type might be caused by an insertional mutation of the Prnp trans-
gene [65].
Genetic or pharmacological ablation or PrPC in macrophages re-
sults in an increased rate of phagocytosis of various apoptotic cells,
indicating that PrPC is a negative regulator of phagocytosis [66].
PrPC has also been shown to promote the swimming internaliza-
tion of Brucella abortus into macrophages through the interaction
with bacterial Hsp60 [67,68]. However, these data are highly con-
troversial and one publication could not reproduce the ﬁnding by
Watarai et al. [69]. Furthermore, another study indicated that PrPC
is expressed on the surface of hematopoietic stem cells and
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survival factor for hematopoietic stem cells [70].
For those functions ascribed to PrPC on the basis of Prnp0/0 mice,
major concerns arise about the possibility of a genetic artifact [71].
For example, alleles in linkage disequilibrium with the deleted
gene (which is constantly selected for by investigators during
breeding) could be actually responsible for the described pheno-
type. Future investigations with Prnp0/0 mice will have to face this
and other caveats, and devise genetically stringent experiments to
assess whether the presumed phenotypes are a primary effect of
Prnp deletion and how this is related to the physiological function
of PrPC.9. Prions and the immune system: a fatal tête à tête
Although prion diseases are neurodegenerative disorders it has
been established already a long time ago that infectious prions do
not only accumulate in the CNS but can also colonize extraneural
organs of infected individuals. Interestingly, in contrast to the cen-
tral nervous tissue prions are not believed to induce tissue damage
in secondary lymphoid organs, although some prion related aber-
rations were reported [72].
It was already shown in the early days of prion immunology
that upon peripheral prion exposure secondary lymphoid organs
appear to play an important role in the development of prion
disease: genetic asplenia or splenectomy of mice prior or after
peripheral prion challenge prolongs the life span of scrapie-in-
fected mice. In contrast, thymectomy or genetic athymia had
no signiﬁcant effect [73] suggesting a dispensable role for T-lym-
phocytes in prion pathogenesis. Further experiments investigated
the cascade of events upon prion exposure in more detail: sple-
nectomy after intraperitoneal (i.p.) prion inoculation revealed
that peripheral prion pathogenesis becomes independent of the
spleen once prions have reached the spinal cord [74]. However,
a splenic replication phase is not obligatory in all rodent TSE
models and might be strain-dependent [43,75]. For example
Tateishi and coworkers have found no effect of splenectomy on
incubation times for the Fukuoka-1 strain, a mouse-adapted
GSS prion [76,77]. This is one of several hints that different prion
strains appear to differ in their tissue tropisms: they are either
lymphotropic, indicating that they colonize lymphoid organs
right after peripheral infection before invading the CNS, or neu-
rotrophic – meaning that they can invade the brain without rep-
licating in the LRS [41,43,44].
Before the invention of ﬂuorescence-activated cell sorting, the
cellular distribution of prions in the LRS was studied by separa-
tion of splenocytes into various subpopulations based on buoyant
density of different adherence of cells to plastic surface [78]. In
these early experiments, it was reported that cells with relatively
high speciﬁc infectivity had a density characteristic of lympho-
blasts, myeloblasts and macrophages. Enrichment of macro-
phages did not enhance scrapie infectivity. Already in these
(relatively crude) fractionation attempts it became clear that
the stromal compartment contained 10 times more prion infec-
tivity than the pulp [79]. Sublethal doses of gamma irradiation,
which affect mitotically active cells of hematopoietic origin but
not resident post-mitotic cells, failed to alter the incubation per-
iod of the disease [80]. These ﬁndings suggested that scrapie rep-
lication or accumulation in the LRS largely depends on
radioresistant, post-mitotic cells localized within the stromal
compartment. However, these experiments did not address the
exact cellular and molecular preconditions needed for efﬁcient
prion transport from the site of entry (e.g. gut) to the LRS and
prion invasion into the CNS.10. Neuroinvasion proper
The use of Prnp0/0 mice [54] and of bone marrow reconstitution
as a technique to generate chimeric mice with stromal and hema-
topoietic compartments of different genotypes revealed a ﬁrst sur-
prise: PrPC itself is involved in transporting prion infectivity from
peripheral sites to the CNS. Titration experiments indicated that
adoptive transfer with wt bone marrow into Prnp0/0 mice reconsti-
tutes the capability of the spleen to accumulate prions of the
mouse-adapted Rocky Mountain Laboratory (RML) scrapie strain
[81–83]. These results were taken to suggest that PrPC-expressing
hematopoietic cells transport prions from the entry site to the
LRS, where prions are efﬁciently replicated. However, the elemen-
tal compartment for prion neuroinvasion appears to be non-hema-
topoietic, since it cannot be adopted by bone marrow
reconstitution [81,82,84].
In conclusion, after peripheral exposure – may this be by inges-
tion or by peripheral infection – prion pathogenesis can be re-
garded as a dynamic process that can be split spatially and
temporally [3]: (1) infection and peripheral prion replication, (2)
prion neuroinvasion and (3) progressive, fatal neurodegeneration.
But what are the exact cellular and molecular mechanisms
underlying those three major stages? Astoundingly, B-lympho-
cytes were demonstrated to be of crucial importance for prion
accumulation in the LRS as well as for neuroinvasion [84]. How-
ever, PrPC expression on B-lymphocytes is not required [85,86].
This combined with the fact that a stromal compartment was
hypothesized to be the essential mediator of neuroinvasion, indi-
cated that B-lymphocytes themselves are unlike to represent a ma-
jor replicative unit for prions. Instead, B-lymphocyte involvement
in peripheral pathogenesis was believed to be indirect, such as sup-
porting the development or maintenance of a prion replicating cell
type that should express PrPC, be – most likely – of stromal origin
and in close proximity to B-lymphocytes.11. FDCs: Cells with the license to replicate prions
The cell fulﬁlling these criteria the most was the FDC. FDCs
accumulate PrPSc following scrapie infection [87], express high lev-
els of PrPC and are localized in close proximity to B-lymphocytes
within splenic and lymph nodal B-cell follicles. Interestingly, FDC
development and maintenance was demonstrated to depend on
tumor necrosis factor (TNF) superfamily members lymphotoxin a
and b (LTa and LTb), which are cytokines mainly produced by B-
lymphocytes, T-lymphocytes and NK cells [88].
Indeed, blockade of LT signaling by administration of a soluble
LTb receptor protein fused to a Fcc portion (LTbR-Ig) ablates ma-
ture FDCs and signiﬁcantly impairs peripheral prion pathogenesis
(Fig. 1) [89]. In line, mice deﬁcient in LT signaling (lta/ or ltbr/
 mice) are largely resistant to peripherally administered prions
[84]. These data for the ﬁrst time directly identiﬁed a cell type to
be involved in peripheral prion pathogenesis in vivo.
FDCs are still poorly described cells, characterized by the expres-
sion ofMfge8 [90]. It is known that FDCs support themaintenance of
the lymphoid microarchitecture, trap immune complexes by Fcc
receptors or by binding opsonized antigens to the CD21/CD35 com-
plement receptors. Indeed, various studies have demonstrated that
the complement components expressedonorboundbyFDCsare rel-
evant to prion pathogenesis: mice genetically engineered to lack
complement factors [91] or mice depleted of the C3 complement
component [92] exhibited enhanced resistance to peripheral prion
inoculation. Further, CD21/35 expressed on FDCswas demonstrated
to be involved in targeting prions to FDCs and expediting neuroinva-
sion following peripheral prion exposure [93].
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It is counterintuitive that FDCs which are sessile cells and of
stromal origin, localized in germinal centers of the LRS, should
be involved in transporting prions to the CNS. It therefore be-
came crucial to ﬁnd the prion entry site to the CNS within sec-
ondary lymphoid organs. Sympathetic nerves, which innervate
lymphoid organs to high degree [94] were hypothesized as a
possible entry port. Therefore, many independent studies have
focused on the role of the sympathetic nervous system in neur-
oinvasion from secondary lymphoid organs to the CNS. Indeed,
these studies indicated that the autonomic nervous system might
be responsible for this process [79,95–97]. In line, sympathec-
tomy delays the onset of experimental scrapie in mice, while
sympathetic hyperinnervation enhances splenic prion replication
and neuroinvasion upon peripheral exposure [98,99]. This sug-
gested that innervation of secondary lymphoid organs might be
indeed the rate limiting step to neuroinvasion [98].
However, there is no direct physical synapse between FDCs
localized in germinal centers and sympathetic nerve endings
[100]. So how do prions march from hot spots of prion replica-
tion to peripheral nerve endings and how do changes in the rel-
ative distance of these two poles affect prion neuroinvasion?
Experimental evidence pointed to the fact that the distance be-
tween FDCs and splenic nerves indeed affects the velocity of
neuroinvasion [101]. FDC positioning was manipulated by abla-
tion of the CXCR5 chemokine receptor, which directs B-lympho-
cytes towards speciﬁc micro-compartments [102]. In this model
the distance between germinal center associated FDCs and
peripheral nerve endings induced superimposition of FDCs and
peripheral nerves [101,102]. CXCR5 deﬁciency did not affect
any aspect of prion pathogenesis within the CNS. However,
although velocity of neuroinvasion was similar in CXCR5/ and
wt mice following peripheral administration of high prion titers,
delivery of smaller titers resulted in a dose dependent increase in
incubation periods in wt when compared to CXCR5/ mice.
Measurement of the kinetics of prion infectivity titers in the tho-
racic spinal cord showed that increased velocity of prion entry
into the CNS of CXCR5/ mice is due to FDCs juxtaposed to
highly innervated, splenic arterioles. This was validated by the
prolongation of incubation periods in CXCR5-/- mice depleted
for mature FDCs [101].
This study also raised the possibility that the spread of infection
to peripheral nerves occurs more rapidly in lymphoid tissues
where FDCs are in near proximity to nerves, such as Peyer’s
patches [103]. Indeed, it was demonstrated that FDCs are crucial
to disease progression for only a very short time window after oral
scrapie challenge: if FDCs are depleted in this time window, mice
will not succumb to scrapie [104].
Although these data have been extremely informative, the ex-
act mechanism of prion transport from FDCs to peripheral nerves
is unknown. Prions could be (1) transported by various cell types
leaving germinal centers towards nerve terminals, (2) incorpo-
rated by murine budding retroviruses, (3) released in FDC-de-
rived exosomes or (4) passively diffuse from the site of
replication to the site of peripheral innervation. Germinal center
B-cells [105] as well as DCs, although previously implicated in
direct prion transport to the CNS [106], were so far excluded
as candidates for the active intrasplenic prion transport [107].
Future experiments will have to reveal the exact mechanisms
of intrasplenic prion transport, which is still one of the key ques-
tions in the ﬁeld of prion immunology.13. Prion replication in inﬂamed organs: a paradigm to study
prion replication competence?
Because lymphoid infectivity is found in most prion diseases
(e.g. sCJD, vCJD, scrapie and CWD) and proinﬂammatory cytokines
and immune cells are involved in lymphoid prion replication
[87,89,101,108–110], it was of interest to test whether chronic
inﬂammatory conditions affect peripheral prion pathogenesis.
Chronic inﬂammation in non-lymphoid organs induced prion rep-
lication at sites that were previously believed to be prion-free
[26,27] including liver, pancreas, kidney or mammary gland. This
ﬁnding, which was initially described in transgenic mice experi-
mentally inoculated with prions, could be reproduced in free rang-
ing, naturally infected sheep or experimentally infected whit-tail
deer [26,111].
All of the inﬂammatory disorders described above shared the
presence of extra follicular structures, the so-called tertiary folli-
cles, which invariably contain FDCs. It was therefore speculated
that prion replication in inﬂammatory foci depends on FDCs: In-
deed, ltbr/ or lta/ mice, which display chronic hepatitis with-
out FDCs, did not replicate prions [27].14. LTbR signaling: from structure to function
Hence, from these and other experiments with ltbr/, lta/ or
ltb/ mice [109] LT signaling was regarded as a mere prerequisite
for FDC development and maintenance [112] rather than directly
linked to enabling peripheral prion replication competence.
However, recently published work of various groups in vitro
and in vivo suggested a more nuanced situation. While crucially
dependent on LT signaling in all conditions investigated, extraneu-
ronal prion replication was found to occur in the absence of immu-
nohistochemically recognizable FDCs in various paradigms: these
included ﬁbroblast or muscle cell lines as well as muscles of a sCJD
patient with myositis (see also Table 1) [24,113–116].
It was therefore hypothesized that extraneuronal prion replica-
tion could potentially take place in inﬂammatory disorders devoid
of FDCs. Therefore, we studied prion replication in subcutaneous
granulomas [117], a very common form of chronic inﬂammation,
expressing PrPC and LTbR, yet lacking FDCs and Mfge8 expression.
After i.p. prion inoculation, Prnp+/+ granulomas, but neither Prnp0/
0 granulomas nor healthy Prnp+/+ skin, accumulated prion infectiv-
ity and PrPSc long before clinical disease. Reciprocal bone marrow
transfers between Prnp+/+ and Prnp0/0 mice revealed that prion
accumulation in granulomas depended on PrPC-expressing stromal
cells. We also took into account that infectivity found in granulo-
mas may represent ‘‘spill-over” from lymphoid organs such as
spleen. However, granulomas of Prnp+/+? Prnp0/0 chimeric mice
completely lacked any prion infectivity, although their spleens dis-
played prion infectivity titers similar to those of wt mice [81–83].
Homogenates of skin located in immediate vicinity of granulomas
lacked prion infectivity in both Prnp+/+ and Prnp0/0 mice at subclin-
ical stage, in agreement with a report that skin may contain prions
only at late stages of disease [118]. These results identiﬁed granu-
lomas as previously unrecognized, clinically silent reservoirs of
prion infectivity.
Further, the nature of the underlying cell type enabling prion
replication in granulomas was investigated by ﬂow cytometry.
We identiﬁed a CD45 negative cell type, expressing high levels of
PrPC and LTbR as well as markers characterizing mesenchymal pro-
genitor cells (MPCs) (e.g. platelet derived growth factor receptor a
M. Nuvolone et al. / FEBS Letters 583 (2009) 2674–2684 2679and b). Whether this cell type resembles a FDC related stromal cell
or even a pre-FDC still remains to be determined.
Administration of LTbR-Ig drastically reduced prion infectivity
of granulomas, although no signiﬁcant changes in PrPC expression
level or frequency of any of the cell populations investigated (e.g.
lymphocytes, macrophages, MPCs) could be detected. Therefore,
lack of prion replication competence in granulomas does not de-
pend on LTbR-Ig induced depletion of particular cell populations
but is rather related to the depletion of LT signaling itself (see also
Fig. 1). This is corroborated by the mRNA downregulation of known
LT target genes (e.g. CCL2) in LTbR-Ig treated granulomas [117].
Therefore, besides being an important prerequisite for mainte-
nance of lymphoid microarchitecture and FDC neogenesis, LT sig-
naling is very likely to enable peripheral prion replication
competence on stromal cell types that are histogenetically differ-
ent from FDCs. These data corroborate previous results that periph-
eral prion replication can occur in the absence of FDCs or PrPC
expressing FDCs in vivo [82,109]. Whether these results can also
be extended to other prion diseased species and different prion
strains is not known and should be investigated in the future.
PrpC has been demonstrated to be necessary but not sufﬁcient
for peripheral prion replication [9], indicating the ultimate require-Fig. 1. Impact of LTbR signaling on peripheral prion replication competence in secondary
granulomas. (A) Peripheral prion replication in secondary or tertiary lymphoid organs is
can be found in splenic white pulp follicles, nodal B-cell follicles or within B-cell clus
granulomas can occur in the absence of FDCs and is most likely accomplished by mesench
LTbR-signaling by repetitive injections of LTbR-Ig dedifferentiates or depletes FDCs in s
infectivity. In granulomas, this is different. Block of LTbR signaling by injection of LTbR-Ig
abolished by LTbR-Ig treatment in granulomas, indicating a functional link between LTbment of additional factors. Future experiments may show whether
PrPC expression in combination with LT signaling would enable
prion replication competence or whether other, yet to be identi-
ﬁed, factors are necessary. In addition, it will be of highest interest
to investigate which LT target genes might be involved in allowing
prion replication competence and how the accrued knowledge can
be translated to understand prion replication competence of
neurons.
15. Manipulating the immune system to prevent or treat prion
diseases
Proverbial sturdiness of prions, lack of a beneﬁcial defensive re-
sponse of hosts upon prion infection and limited understanding of
the physiological functions of PrPC hamper the development of efﬁ-
cient interventional strategies against prion diseases.
On the other hand, in recent years accrued knowledge about the
role of the immune system in prion pathogenesis has encouraged
investigators to explore the feasibility of various interventional
strategies against prion diseases [119]. Repeated administration
of cytidyl guanosyl containing oligodeoxynucleotides (CpG-ODN)
– mimicking unmethylated bacterial DNA and stimulating the in-lymphoid organs, chronic lymphocytic inﬂammation (tertiary lymphoid organs) and
mainly accomplished by PrPC+/LTbR+/Mfge8+ follicular dendritic cells (FDCs). Which
ters of inﬂammatory foci. In contrast, replication of PrPSc and prion infectivity in
ymal progenitor cells (MPCs), which are PrPC+/LTbR+/Mfge8/PDGFRab+. (B) Block of
econdary lymphoid organs and leads to a drastic decrease in PrPSc load and prion
does not deplete or dedifferentiate PrPC+ MPCs. Still, prion replication competence is
R-signaling and prion replication competence in PrPC+ MPCs.
Table 1
List of cultured cells capable of replicating prions. Black rectangles indicate permissiveness of cells or cell lines to replicate a particular prion strain.
setalosirosniartsnoirP
Cell type Species Tissue or cell of origin 
C
h
a
n
d
l
e
r
 
C
o
m
p
t
o
n
 
R
M
L
 
1
3
9
A
 
2
2
L
 
2
2
F
 
M
E
7
 
C
5
0
6
 
3
0
1
C
 
R
o
d
e
n
t
-
B
S
E
 
F
U
 
S
Y
 
C
J
D
 
N
a
t
u
r
a
l
 
s
c
r
a
p
i
e
 
H
a
m
s
t
e
r
 
p
r
i
o
n
s
 
C
W
D
 
Comments Ref. 
N1E-115 Mouse Neuroblastoma ]331[
C-1300 Mouse Neuroblastoma ]431[
N2a Mouse Neuroblastoma ]431[
N2a#58 Mouse Subclone of N2a      N2a overexpressing PrPC [135] 
N2a-PK1 Mouse Subclone of N2a   ]64[
N2a-R33 Mouse Subclone of N2a     ]611[
SHSY-5Y Human Neuroblastoma             ]631[
PC12 Rat Pheochromocytoma             neuronal differentiation with nerve growth factor [137] 
GT1-1 Mouse Hypothalamic neuronal cells subclon 1 ]831[
GT1-7 Mouse Hypothalamic neuronal cells subclon 7 ]831[
SN56 Mouse Hybrid septal neuron/neuroblastoma ]931[
CAD-2A2D5 Mouse CNS catecholaminergic cell line          neuronal differentiation by serum deprivation [116] 
HpL3-7 Mouse Hippocampal cells     ]041[
CGNov Mouse Cerebellar granule neurons                from transgenic mouse expressing ovine PrPC [141] 
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NSC Mouse Neural stem cells   ]241[
SMB Mouse Mesodermal cells                from scrapie-infected mouse brain [143] 
SMB-PS Mouse Pentosan sulfate-cured SMB ]441[
L-fibroblast Mouse Subclone of L929 fibroblast cells ]541[
L23 Mouse Subclone of L929 fibroblast cells  ]641[
L929 Mouse Fibroblast cells   ]741[
LD9 Mouse Subclone of L929 fibroblast cells   ]611[
NIH/3T3 Mouse Fibroblast cells     ]741[
NS1 Mouse Fusing spleen cell with NS1 cell                spleen cell from scrapie-infected mouse [148] 
Glial cell Rat Glial cells from rat trigeminal ganglion                ethiylnitrosourea-induced ganglion tumor [149] 
HaB Hamster Non-neuronal hamster brain cells                spontaneously immortalized cells [150] 
MG20 Mouse Microglial cells ]151[
CAS Mouse Cerebellar astrocytes                from transgenic mouse expressing ovine PrPC [141] 
MSC-80 Mouse Schwann cells ]251[
MovS Mouse Schwann-like cells from DRG                from transgenic mouse expressing ovine PrPC [153] 
MDB Deer Fibroblast-like cells                ]451[
Rov Rabbit Epithelial RK13            RK13 cells expressing ovine PrPC [155] 
voRK13 Rabbit Epithelial RK13                 RK13 cells expressing bank vole PrPC [156] 
moRK13 Rabbit Epithelial RK13      RK13 cells expressing murine PrPC [157] 
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C2C12 Mouse Myoblasts                in co-culture with 22L-infected N2a cells [113] 
301C: a mouse-adapted bovine spongiform encephalopathy prion strain; FU: Fukuoka-1, a mouse-adapted Gerstmann–Sträussler–Schinker disease prion strain; SY: a mouse-adapted sporadic Creutzfeld–Jakob disease prion strain;
CJD: a patient-derived Creutzfeld–Jakob disease prion isolate; CWD: chronic wasting disease prion isolate; PrPC: cellular prion protein.
See [133–157].
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M. Nuvolone et al. / FEBS Letters 583 (2009) 2674–2684 2681nate immune system through Toll-like receptor 9 (TLR9) – was
able to extend the survival of peripherally prion-inoculated mice.
This observation suggested a potential role of CpG-ODN based reg-
imens in post-exposure prophylaxis against prion diseases [120].
However, this ﬁnding was difﬁcult to reconcile with the knowledge
that various types of immune deﬁciencies confer resistance to
peripherally administered prions and with the unaltered prion
pathogenesis in myd88/ mice, in which TLR9 signaling is im-
paired [121]. Subsequent investigations showed that repeated
CpG-ODN administration results in immunosuppression and lym-
phoid follicle destruction, a fact that could per se well explain
the alleged anti-prion properties of this regimen [122].
In 1988 Gabizon et al. found that in vitro exposure of infectious
hamster brain homogenate to anti-PrP antisera resulted in the
reduction of the infectivity titer [123]. Later, anti-PrP antibodies
proved to efﬁciently inhibit the formation of protease-resistant
PrP in cell-free systems [124] and to suppress prion replication
in cultured cells [125,126].
While these data constitute a rational for the development of
anti-prions immunotherapy, achievement of active immunization
against PrP is hampered by essential tolerance of the mammalian
immune system to PrPC. In an ingenious model, transgenic
expression of an immunoglobulin l chain containing the epi-
tope-interacting region of a high-afﬁnity anti-PrP antibody cir-
cumvented the tolerance and resulted in build-up of anti-PrPC
titers and prevention of prion pathogenesis upon i.p. prion inocu-
lation [127]. Sigurdsson et al. succeeded to induce active immuni-
zation in wt mice with recombinant prion protein, achieving a
modest therapeutic effect [128]. The observation that antibodies
generated against bacterially expressed PrP often display low
afﬁnity towards native cell-surface PrPC [129] might explain the
limited therapeutic results obtained with this approach. Several
others studies have shown successful circumvention of immuno-
logical tolerance to PrP with development of a protective B-cell
mediated response against prions, including a recent report of
effective mucosal vaccination protecting against oral prion infec-
tion through oral administration of PrP expressed in an attenu-
ated Salmonella vector [130].
An obvious and more practical alternative to vaccination aimed
at achieving protective anti-prion immune response is passive
immunization. Passive transfer of anti-PrP antibodies shortly after
peripheral prion inoculation succeeded to delay the onset of prion
disease [131]. However, no beneﬁcial effect was seen when the
antibodies were administered at onset of clinical signs, suggesting
that passive immunization might be a good candidate for post-
exposure prophylaxis rather than for therapy of TSEs.
Given the potential of antibodies to interfere with prion patho-
genesis it was disappointing that intracranial delivery of speciﬁc
anti-PrP antibodies has resulted in rapid and extensive apoptosis
in hippocampal and cerebellar neurons [132]. Data in this study
suggested that this occurs possibly through cross-linking of PrPC,
assumed to trigger an abnormal signaling pathway [132]. These
ﬁndings emphasize the need for scrupulous in vivo safety studies
before the feasibility of prion immunoprophylaxis trials in humans
can be considered.
The relevance of LT signaling in peripheral prion replication has
indicated inhibition of this pathway as a promising strategy
against prion diseases. In particular, treatment with LTbR-Ig might
represent a plausible candidate for early post-exposure prophy-
laxis, namely iatrogenic or occupational exposure (e.g. blood trans-
fusion, medical accidents). Interestingly, LTbR-Ig (baminercept a)
proteins have already entered clinical trials as a treatment for
rheumatoid arthritis and preliminary results concerning the safety
of this drug are encouraging [88]. Additionally, other immunosup-
pressive reagents (e.g. corticosteroids) could be efﬁciently used to
prevent peripheral prion accumulation or replication.16. Prion diseases: future perspectives
The last years of prion research have accumulated an enormous
wealth of data widening our horizon about how prions accomplish
peripheral replication, horizontal transmission and neurodegener-
ation. Although prion diseases represent the only class of neurode-
generative disorders in which scientists have at least a grasp on
how neurotoxicity is exerted, our knowledge is not sufﬁcient to
halt or reverse the pathological process in the brain. On the posi-
tive side it is worth mentioning that we have started to understand
the details of how and where prions can be replicated and horizon-
tally transmitted. This should pave the way for preventing pan-
demic outbreaks of known, potentially human pathogenic prion
strains (e.g. BSE) in the future. However, as prion research has indi-
cated in the past, new prion strains are on the rise (e.g. CWD) that
potentially might represent a health risk to humans. Therefore,
in vivo models to identify potentially human pathogenic prion
strains are urgently needed. Although the BSE crisis has been re-
solved and the numbers of vCJD cases are decreasing, we have little
knowledge about the distribution of prion infectivity within the
general population and for how long this prion infectivity can be
conveyed in subclinical carriers leading to unprecedented human
to human transmissions.
The above indicates that we are just at the beginning of a jour-
ney into the details of the prion universe, that will lead us to new
surprises, challenges and serendipities in the future – most likely
also highly useful for understanding other neurodegenerative and
infectious disorders.Acknowledgments
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